Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: HLX02|BIOLOGICAL: Herceptin®|DRUG: docetaxel
Sponsor: Shanghai Henlius Biotech